Payment overview · 2025
General Payments
$4,175.84
107 reported records · 16 companies
Healthcare provider profile · identity verified
Quentin Orlando
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · ERIE, PA · NPI 1861660409
Verified facts
What the public records show
CMS Open Payments records show Quentin Orlando received $4,175.84 in general payments during 2025 across 107 reported records.
Edwards Lifesciences Corporation accounted for 30.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $1,265.37 | 30.3% | 21 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $701.15 | 16.8% | 26 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$649.29 | 15.6% | 15 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $345.83 | 8.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $242.89 | 5.8% | 10 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $221.19 | 5.3% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $146.97 | 3.5% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $145.77 | 3.5% | 7 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $125.80 | 3.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $120.77 | 2.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $102.72 | 2.5% | 6 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $41.71 | 1.0% | 3 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $18.14 | 0.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.41 | 0.4% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $17.13 | 0.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.70 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,175.84 | 107 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $1,156.13 | 19 | 2025 |
Source payment records
|
|||||
| RESOLUTE ONYX Normalized: resolute onyx |
Device | Medtronic, Inc. | $368.07 | 9 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $164.40 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $155.52 | 8 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $145.34 | 2 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $135.88 | 4 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $130.18 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $130.18 | 1 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $126.16 | 1 | 2025 |
Source payment records
|
|||||
| GUIDELINER Normalized: guideliner |
Device | Teleflex LLC | $125.80 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $120.77 | 3 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $109.24 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $99.90 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $91.01 | 3 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $77.53 | 5 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $57.81 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.63 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $53.63 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $41.71 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Access Normalized: general vascular access |
Device | Boston Scientific Corporation | $20.81 | 2 | 2025 |
Source payment records
|
|||||
| ANGIO-SEAL Normalized: angio seal |
Device | Terumo Medical Corporation | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| GLIDEWIRE Normalized: glidewire |
Device | Terumo Medical Corporation | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| TR BAND Normalized: tr band |
Device | Terumo Medical Corporation | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $0.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 254 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 243 | 72 |
| Atorvastatin Calcium | Atorvastatin Calcium | 227 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 219 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 64 |
| Carvedilol | Carvedilol | 111 | 31 |
| Ezetimibe | Ezetimibe | 109 | 33 |
| Losartan Potassium | Losartan Potassium | 99 | 30 |
| Lisinopril | Lisinopril | 78 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 23 |
| Spironolactone | Spironolactone | 59 | 18 |
| Nitroglycerin | Nitroglycerin | 37 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 36 | 14 |
| Bumetanide | Bumetanide | 35 | 13 |
| Brilinta | Ticagrelor | 34 | suppressed |
| Eliquis | Apixaban | 32 | suppressed |
| Furosemide | Furosemide | 29 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Prednisone | Prednisone | 23 | 18 |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,175.84 · 107 records | Edwards Lifesciences Corporation | ANGIO-SEAL, CAMZYOS, COREVALVE EVOLUT R, CT THROMBECTOMY SYSTEM KIT, DIAMONDBACK CORONARY, ELIQUIS, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, GLIDEWIRE, GUIDELINER, General - Balloon Catheters, General - Vascular Access, JARDIANCE, LEQVIO, LifeVest, MYNX CONTROL VENOUS, NAVITOR, NURTEC ODT, PAXLOVID, REPATHA, RESOLUTE ONYX, SAPIEN 3 Ultra RESILIA, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TR BAND, VYNDAQEL, XIENCE SKYPOINT | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error